Containing Solid Synthetic Polymers Patents (Class 424/497)
  • Patent number: 10656147
    Abstract: Methods and apparatus for processing fluids on a macro- or micro-scale are described. In various aspects, a fluid may have a plurality of elongated (i.e., substantially rod-shaped) magnetic elements disposed therein within a fluid container. An illustrative fluid container is an actuator electrode or a processing vial of a microfluidic device, such as a digital microfluidic device. A magnet component may be configured to generate a magnetic force sufficient to influence the movement of the plurality of elongated magnetic elements within the fluid to be processed. For example, the magnetic force (or magnetic force gradient) may influence the plurality of elongated magnetic elements to rotate, spin, and/or move laterally side-to-side. The shape and movements of the plurality of elongated magnetic elements facilitate the rapid and efficient processing of the fluid, such as fluid mixing and/or fluid separation.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 19, 2020
    Assignee: DH Technologies Development Pte. Ltd.
    Inventors: John L. Campbell, Thomas R. Covey, Chang Liu, Subhasish Purkayastha
  • Patent number: 10561621
    Abstract: A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 ?m to 20 ?m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: February 18, 2020
    Inventors: Diane Goll, Cecil W. Propst
  • Patent number: 10543285
    Abstract: In one aspect, methods of targeted nanoparticle and cell delivery are described herein. In some embodiments, methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 28, 2020
    Assignee: The Penn State Researh Foundation
    Inventors: Jian Yang, Cheng Dong, Zhiwei Xie
  • Patent number: 10545135
    Abstract: The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: January 28, 2020
    Inventor: Geeta Shroff
  • Patent number: 10543203
    Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Emplicure AB
    Inventors: Susanne Bredenberg, Anna Dahlgren, Anders Sågström, Håkan Engqvist
  • Patent number: 10517962
    Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 31, 2019
    Assignees: Universite Claude Bernard Lyon I, Nano-H, Universite Grenoble Alpes, Universite de Bordeaux, Centre National de la Recherche Scientifique
    Inventors: Yannick Cremillieux, Andrea Bianchi, Sandrine Dufort, Jean-Luc Coll, Francois Lux, Olivier Tillement
  • Patent number: 10363309
    Abstract: A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder.
    Type: Grant
    Filed: February 5, 2012
    Date of Patent: July 30, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: James Basilion, Clemens Burda
  • Patent number: 10293077
    Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: May 21, 2019
    Assignees: The Regents of the University of California, The Board of Trustees of the University of Illinois
    Inventors: Damien Kudela, Galen D. Stucky, Anna May-Masnou, Gary Bernard Braun, James H. Morrissey, Stephanie A. Smith
  • Patent number: 10238709
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 26, 2019
    Assignee: Chiasma, Inc.
    Inventors: Roni Mamluk, Sam L. Teichman
  • Patent number: 10206882
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 19, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Patent number: 10207003
    Abstract: Provided herein are amphiphilic polymers compositions for making aqueous formulations. In one aspect, a solution composition for delivery and release of active ingredients comprises a block co-polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA or PLA-PCL-PEG-PCL-PLA or PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL. The block co-polymers are biodegradable, stable and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents. In some embodiments, the block co-polymers enable sustained and/or continuous release of various active agents. In certain embodiments, the block co-polymers can be used to make an artificial tear preparation, a lubricant for joints or wound cover or adhesive.
    Type: Grant
    Filed: April 29, 2017
    Date of Patent: February 19, 2019
    Assignee: inovion, Inc.
    Inventors: Poonam R. Velagaleti, Brian C. Gilger, Ulrich Grau, Rasidul Amin, Santhi Abbaraju
  • Patent number: 10195571
    Abstract: Multiple emulsions and techniques for the formation of multiple emulsions are generally described. A multiple emulsion, as used herein, describes larger droplets that contain one or more smaller droplets therein. In some embodiments, the larger droplet or droplets may be suspended in a carrying fluid containing the larger droplets that, in turn, contain the smaller droplets. As described below, multiple emulsions can be formed in one step in certain embodiments, with generally precise repeatability, and can be tailored in some embodiments to include a relatively thin layer of fluid separating two other fluids.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: February 5, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Weitz, Shin-Hyn Kim, Alireza Abbaspourrad
  • Patent number: 10183001
    Abstract: An abuse deterrent drug product is provided wherein the drug product comprises a matrix and a drug substance in the matrix wherein the drug substance is defined as a 1:1 salt of a pharmaceutically active compound and BNDO.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 22, 2019
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Patent number: 10172956
    Abstract: The presently-disclosed subject matter includes nanoparticles that comprise a plurality of assembled polymers. In some embodiments the polymers comprise a first block that includes hydrophilic monomers, the first block substantially forming an outer shell of the nanoparticle, and a second block that includes cationic monomers and hydrophobic monomers, the second block substantially forming a core of the nanoparticle. In some embodiments a polynucleotide is provided that is bound to the cationic monomers of the nanoparticle. The presently-disclosed subject matter also comprises methods for using the present nanoparticles to include RNAi in a cell as well as methods for making the present nanoparticles.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: January 8, 2019
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, Christopher E. Nelson, James Kintzing, Joshua M. Shannon, Mukesh K. Gupta, Scott A. Guelcher, Elizabeth J. Adolph, Jeffrey M. Davidson
  • Patent number: 10159661
    Abstract: The present invention is directed to an injection syringe comprising an injectable composition, the composition comprising a penicillin, salt or prodrug thereof, one or more pharmaceutically acceptable excipients, and water, wherein the composition is free of a preservative agent. In other aspects, the invention relates to a process for producing the injection syringe, and a kit comprising the injection syringe.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: December 25, 2018
    Assignee: Sandoz AG
    Inventors: Christoph Bitter, Heiko Degendorfer, Johannes Raneburger
  • Patent number: 10105322
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 23, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 10076572
    Abstract: Effective Photodynamic therapy (PDT) against C. difficile is provided using a composition including chitosan and tetracycline.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: September 18, 2018
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Hiun Suk Chae, Sung Sook Choi
  • Patent number: 10046065
    Abstract: A nucleic acid-encapsulating polymer micelle complex is formed of a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polymer chain block; and two single-stranded DNA molecules having mutually complementary base sequences of 1000 or more bases in length, double-stranded DNA of 1000 or more base pairs in length in which at least a part of a double helix structure is dissociated and forms a single-stranded structure, or one single-stranded DNA molecule of 1000 or more bases in length.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: August 14, 2018
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Kensuke Osada, Theofilus Agrios Tockary
  • Patent number: 10022373
    Abstract: The present invention relates to a pharmaceutical composition comprising posaconazole and a carrier material, wherein the carrier material comprises a vinylpyrrolidone-vinyl acetate copolymer or a polymer containing ethylene glycol units. The present invention also relates to a method for the preparation of the pharmaceutical composition, a method for the prevention and/or treatment of fungal infections and related diseases in a mammal using the pharmaceutical composition, and a pharmaceutical formulation comprising the pharmaceutical composition.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: July 17, 2018
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Jiansheng Wan, Kun Li, Xiaoxi Sheng
  • Patent number: 10000447
    Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 19, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Joseph E. Payne, John A. Gaudette, Zheng Hou, Victor Knopov, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Violetta Akopian
  • Patent number: 9988517
    Abstract: Microsphere compositions containing a mixture of at least two materials with same or differing phases are described. The materials have differing optical dispersion curves that intersect at at least one particular wavelength exhibiting the Christiansen effect. The materials may be encompassed by a microsphere, which may also include a separation entity.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: June 5, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventors: Sung-Wei Chen, Christopher J. Rothfuss
  • Patent number: 9982090
    Abstract: The present invention relates to a method for manufacturing polydioxanone particles (PDO) for a filler, more particularly to a method for manufacturing polydioxanone particles, which includes a step of mixing a solution of polydioxanone dissolved in a perfluoroalcohol with a polymer emulsion containing a polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer at a predetermined ratio to generate polydioxanone particles and then recovering the polydioxanone particles through aging and washing. The polydioxanone particles manufactured by the manufacturing method of the present invention can be favorably used as an injection for regenerating skin tissues.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: May 29, 2018
    Assignee: ULTRA V CO., LTD.
    Inventors: Myung Choi, Sang Jin Kim, Byeung Mo Chang, Michael Gilbert Douglas, Han Jin Kwon
  • Patent number: 9925212
    Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Relypsa, Inc.
    Inventors: Gerrit Klaerner, Lance Berman
  • Patent number: 9907977
    Abstract: The present disclosure relates to the cross-linking of eye tissue. Embodiments of the disclosure relate to the activation of a photosensitizer and/or nanoparticles for the cross-linking of eye tissue.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 6, 2018
    Assignee: Novartis AG
    Inventor: Katrin Skerl
  • Patent number: 9849128
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 26, 2017
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon
  • Patent number: 9802165
    Abstract: This invention relates to bubble generation, in particular to microbubble generation in a microfluidic device, which bubbles may be useful as contrasting agents or drug delivery vehicles. The invention further relates to apparatuses, systems and methods for manufacturing said microbubbles, microbubbles produced by such methods and to their uses, e.g. in medical, diagnostic and other such applications. The microbubbles are preferentially formed using a microspray regime.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 31, 2017
    Assignee: The University of Leeds
    Inventors: Sally Anne Peyman, Radwa Hassan Abou-Saleh, Stephen Derek Evans
  • Patent number: 9782484
    Abstract: The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: October 10, 2017
    Assignee: ACTIVUS PHARMA CO., LTD.
    Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
  • Patent number: 9764305
    Abstract: A principle is established to show that nanoscale energy deposition in water by X-rays can be greatly enhanced via the geometry of nanostructures. The calculated results show that enhancement over background water can reach over 60 times for a single nanoshell made of gold. Other geometries and nanostructures are investigated, and it is found that a shell of gold nanoparticles can generate similar enhancement. The concepts of composition, matrix, and satellite effects are established and studied, all of which can further increase the enhancement of the effect of X-rays.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 19, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Ting Guo
  • Patent number: 9757331
    Abstract: Stable solid compositions have a first carrier and an adsorbate having at least one active component, such as, a vitamin D derivative and a hydrophobic stabilizer thereof, wherein the first carrier is a calcium phosphate or derivatives thereof having a solubility in water lower than 0.1 wt % at room temperature.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: September 12, 2017
    Assignee: PRAYON SA
    Inventors: Khadija Tantaoui Elaraqi, Guy Broze, Audrey Leruite
  • Patent number: 9717695
    Abstract: The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.
    Type: Grant
    Filed: May 18, 2013
    Date of Patent: August 1, 2017
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Didier Merlin, Bo Xiao, Hamed Laroui
  • Patent number: 9709501
    Abstract: The present invention relates to an in vitro method for diagnosing the infectious state of an individual on the basis of a sample of white corpuscles arising from a biological specimen taken from an organ potentially infected by a pathogenic microorganism of said individual, comprising at least the following two steps: i) measuring the mean cellular intensity of the autofluorescence of said sample, and ii) comparing the intensity measured in step i) with a control value, so as to determine the infectious state of said individual. The diagnostic method of the invention uses a routine optical material making it possible to work in wavelength regions which are compatible with the cellular autofluorescence, and thus constitutes a rapid, reliable and inexpensive aid for the diagnosis or monitoring of an infection in an individual.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: July 18, 2017
    Assignees: UNIVERSITE DE NANTES, UNIVERSITE PARIS-SUD 11, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Karim Asehnoune, Marie-Pierre Fontaine-Aupart, Sandrine Lecart, Antoine Monsel, Antoine Roquilly
  • Patent number: 9707548
    Abstract: Provided are a polymer capsule loaded with transition metal particles having excellent water dispersibility and stability, and a method for preparing the same. Specifically, the polymer capsule loaded with transition metal particles according to the present invention includes a surface-modified polymer capsule surface-modified to thereby have a positive zeta potential in a dispersed state in water; and transition metal particles loaded on a surface of the surface-modified polymer capsule. In addition, a method for preparing a polymer capsule loaded with transition metal particles according to the present invention includes a) preparing a polymer capsule; b) surface-modifying the polymer capsule to prepare a polymer capsule having a positive zeta potential in a dispersed state in water; and c) sequentially adding a water-soluble transition metal precursor and a reducing agent to a water dispersion of the surface-modified polymer capsule obtained in step b).
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 18, 2017
    Assignees: INSTITUTE FOR BASIC SCIENCE, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Kimoon Kim, Gyeongwon Yun, Zahid Hassan, Jiyeong Lee, Jeehong Kim, Nam Hoon Kim, Kangkyun Baek, Iiha Hwang
  • Patent number: 9700530
    Abstract: This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 11, 2017
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Sandeep Kumar Vats, Balaram Mondal, Kalaiselvan Ramaraju, Romi Barat Singh
  • Patent number: 9687452
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 27, 2017
    Assignee: Curemark, LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 9675711
    Abstract: Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particularly preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalized by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: June 13, 2017
    Assignee: The Johns Hopkins University
    Inventors: Jung Soo Suk, Justin Scot Hanes
  • Patent number: 9622972
    Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterized in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: April 18, 2017
    Assignee: Emplicure AB
    Inventors: Susanne Bredenberg, Anna Dahlgren, Anders Sågström, Håkan Engqvist
  • Patent number: 9527040
    Abstract: Continuous processes for depleting residuals in hollow fiber membranes comprising polysulfone or polyethersulfone and polyvinylpyrrolidone by rinsing the membranes while compressing them in a pinching device comprising grooved rollers.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: December 27, 2016
    Assignee: GAMBRO LUNDIA AB
    Inventors: Bernd Krause, Carina Zweigart, Christof Beck, Bernd Hertzler, Steffen Wagner, Joachim Loercher
  • Patent number: 9504655
    Abstract: The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 29, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Sandeep Kumar Vats, Balaram Mondal, Kalaiselvan Ramaraju, Romi Barat Singh
  • Patent number: 9492476
    Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 15, 2016
    Assignee: Relypsa, Inc.
    Inventors: Gerrit Klaerner, Lance Berman
  • Patent number: 9480640
    Abstract: A nano freeze dry process of preparation for a cosmetic composition having a bioactive agent for providing an anti-aging effect on a skin, comprising the steps of: placing the cosmetic composition having a bioactive agent into a capsule container; and nano freeze drying the cosmetic composition by: freezing the cosmetic composition in the capsule container at ?170° C.; increasing the temperature to ?85° C. and allowing sublimation under vacuum condition; then increasing the temperature to 35° C.; and vacuum drying to obtain a final product, wherein a volume of the cosmetic composition remains unchanged after the process, a water content of less than 5% is inside the final, at least 80% of bioactivity of the cosmetic composition is retained, and significant anti-aging effect is observed after a two-day treatment.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: November 1, 2016
    Inventor: Hongkai Zhang
  • Patent number: 9457099
    Abstract: The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: October 4, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Jieming Gao, Yashveer Singh, Xiaoping Zhang, Matthew S. Palombo, Stanley Stein
  • Patent number: 9421246
    Abstract: Provided are ingestible polymeric formulations and oral dosage forms for the reduction of gastric volume in the treatment of overweight and obese patients. The formulation includes an acid-sensitive, gelatin coating over a dehydrated hydrophilic polymer. When ingested, the acid-sensitive coating is quickly dissolved by gastric secretions and the hydrophilic polymer is exposed to the aqueous environment of the gastric milieu. The polymer absorbs water and expands to the point that will not allow the polymer to pass beyond the pyloric valve, and the expanded polymer is therefore trapped in the stomach.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: August 23, 2016
    Assignee: BAROnova, Inc.
    Inventors: Daniel R. Burnett, Peter G. Edelman
  • Patent number: 9381156
    Abstract: A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particles. Further, the emulsification system includes at least one nonionic emulsifier. The emulsion has a viscosity ranging from about 500 centipoise to about 10,000 centipoise and a hydrophilic to lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsification system and the viscosity of the emulsion, the active agent particles resist settling such that a substantially homogeneous distribution of the active agent particles is maintained and can be evenly sprayed onto a surface without running once applied.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: July 5, 2016
    Assignee: Mission Pharmacal Company
    Inventors: Thomas Dann, Renee Nelson, Brian Wagner, Mary Walter
  • Patent number: 9346682
    Abstract: The present document describes a microcapsule having silica shells, processes for making the same, processes for functionalizing said microcapsules and processes for encapsulating active agent in said microcapsules.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 24, 2016
    Assignee: LES INNOVATIONS MATERIUM
    Inventors: Mathilde Gosselin, Shaoyong Yu, Nabil Ghezal, Cé Guinto Gamys
  • Patent number: 9339485
    Abstract: The present invention provides for a method to increase the triplet yield of a photosensitizer by the coupling to metal surface plasmons which leads to increased singlet oxygen generation by electric field enhancement or enhanced energy absorption of the photosensitizer. The extent of singlet oxygen enhancement can be tuned for applications in singlet oxygen based clinical therapy by modifying plasmon coupling parameters, such as metallic nanoparticle size and shape, photosensitizer/metallic nanoparticle distance, and the excitation wavelength of the coupling photosensitizer.
    Type: Grant
    Filed: January 27, 2008
    Date of Patent: May 17, 2016
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Chris D. Geddes
  • Patent number: 9278070
    Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: March 8, 2016
    Assignee: Sigmoid Pharma Limited
    Inventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
  • Patent number: 9259395
    Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: February 16, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ick Chan Kwon, Kwang Meyung Kim, Kuiwon Choi, Heebeom Koo, Hyun Su Min, Inchan Youn
  • Patent number: 9186640
    Abstract: A complex coacervate delivery system is provided which encapsulates lipophilic nutrients such as, for example, fish oils high in omega-3 fatty acids. The complex coacervate delivery system protects the lipophilic nutrient from degradation, e.g., oxidation and hydrolysis, and also reduces or eliminates the unpleasant taste and odor of the lipophilic nutrient. The complex coacervate delivery system upon ingestion is operative to substantially release the lipophilic nutrient in the lower gastrointestinal tract in a pH-controlled manner. The complex coacervate delivery system may be included in a food or beverage product having a pH value within the range of about 1.5 to about 5.0.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: November 17, 2015
    Assignee: PepsiCo, Inc.
    Inventors: Daniel S. Kohane, Yoon Yeo, Peter Given, Robert S. Langer
  • Patent number: 9125835
    Abstract: Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: September 8, 2015
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Jieming Gao, Manjeet Deshmukh, Xiaoping Zhang, Matthew S. Palombo, Sherif Ibrahim
  • Patent number: 9120125
    Abstract: The present invention includes systems, methods and compositions for the encapsulation of particles. In one form, the system comprises one or more particles, a rotatable reaction chamber in a plasma enhanced chemical reactor to accept one or more particles, and at least one carbonaceous compound to be used in the rotatable reaction chamber, wherein the carbonaceous compound is polymerized onto a surface of one or more particles forming a polymer film encapsulating one or more particles. Using systems, methods, and compositions of the present invention, any particle encapsulated with a degradable or nondegradable polymer film may be introduced and/or released into an environment. The polymer film as well as introduction of encapsulated particles and release therefrom into an environment are controlled by the present invention.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: September 1, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard B. Timmons, Ceren Susut